復星醫藥11億美元收購印度藥企交易出現變數
India has balked at the planned $1.1bn purchase of Hyderabad-based Gland Pharma by China’s Shanghai Fosun Pharma, amid concerns about allowing a foreign takeover of a producer of the export-quality medicines.
The two companies announced last July that Fosun would take an 86 per cent stake in Gland, which produces anti-coagulants — used in dialysis or heart surgery to prevent blood-clotting — anaesthetics and other injectable medicines, mainly for export to the US.
去年7月，兩家公司宣佈，復星將收購Gland 86%的股權，後者生產抗凝血劑（用於透析或心臟手術，防止血液凝固）、麻醉劑及其他注射藥劑，主要出口美國。But New Delhi’s Cabinet Committee on Economic Affairs, which must give the final greenlight for a deal already approved by various Indian ministries, has been sitting on the proposal for the past four months.
但新德里的內閣經濟事務委員會(CCEA)過去4個月一直拖延審批這項收購。印度各部委已批准這筆交易，但仍須由該委員會開啓最後的綠燈。
“The concern is about India losing its edge on a particular drug where it has a significant presence internationally, as well as its access to our own market,” an Indian official, who did not want to be named, told the FT.
一位不願透露姓名的印度官員對英國《金融時報》表示：“印度擔心失去在國際上擁有重要地位的特定藥品上的優勢，以及該藥品進入我國市場。”The official told the FT no final decision had been taken on the transaction, but that “there is a serious enough concern that it is likely to bring a negative outcome”.
這位官員對英國《金融時報》表示，對於這筆交易尚未做出最終決定，但“印方的擔憂如此嚴重，結果很可能是交易被否決”。Gland shareholders say they have not received any official notice of New Delhi’s objection to the deal, which is the largest proposed takeover of an Indian company by a firm from China — a country with which New Delhi has uneasy Relations.
Gland的股東表示，他們尚未收到新德里否決該交易的任何官方通知，這是中國企業對印度企業提出的規模最大的一筆併購交易。中印之間目前處於關係緊張狀態。Relations between the countries have deteriorated recently following a territorial dispute in the Himalayas involving India ally Bhutan. Indian officials stressed that their concern about the Gland Pharma sale was not “country-specific”.
近期，喜馬拉雅山地區涉及印度盟國不丹的一場領土爭端導致中印關係惡化。印度官員強調，他們對於Gland Pharma被收購的擔憂並非“針對某個國家”。Fosun Pharma confirmed the two companies had extended the “termination date” for the deal to September 26, given the lack of a final decision from India’s CCEA.
復星醫藥證實，鑑於印度內閣經濟事務委員會尚未作出最終決定，兩家公司已將交易“終止日期”延長至9月26日。Fosun Pharma said that the Chinese government had given all the necessary approval for the purchase to proceed.
復星醫藥表示，中國政府已經審批通過了這筆收購交易的所需的所有程序。
